Soligenix Issues Interim Results For CTCL Treatment Trial 75% Response At 18 Weeks, 3 Patients Achieve Complete Response

About this update from Soligenix, Inc.

[{"type":"text","content":"By JE Insights, Benzinga\nDETROIT, MICHIGAN - May 5, 2025 (NEWMEDIAWIRE) - Late-stage biopharmaceutical company Soligenix, Inc. (NASDAQ: SNGX) focuses on developing treatments for rare and underserved diseases. Primarily, the firm specializes in providing groundbreaking treatments for critical conditions with few effective options. Among its most promising lead programs is HyBryteTM, which targets cutaneous T-cell lymphoma (CTCL) - a chronic, difficult-to-treat skin cancer.\n With no approved frontline therapies currently available, HyBryte's potential to fill this much-needed gap has drawn growing attention. Recently, Soligenix released interim results from a real-world study funded by the U.S. Food and Drug Administration (FDA). The results reinforce earlier late-stage clinical data and further position HyBryte as a relevant first-line treatment.\nDecoding The Architecture Of HyBryte And Its Key Indication\nDeveloped as a topical drug, HyBryte's main indication or its treatment focus is CTCL, a rare, chronic cancer where malignant T-cells migrate to the skin and cause lesions. According to the Mayo Clinic, CTCL is a type of non-Hodgkin lymphoma. Often, the cause of the condition - which results in a growth of cells in the skin - isn't known. However, demographic risk factors include being over the age of 50, though the condition can happen at any time.\nIn terms of numbers, CTCL affects around 31,000 people in the U.S. and approximately 38,000 people in Europe. For patients, the high unmet need represents a significant burden. Simultaneously, though, the limited competition creates an opportunity for a disruptive innovation, especially one that involves the potential to transition to broad, home-use applications.\nA key concern about CTCL is that it often resembles the more common and manageable conditions of psoriasis or eczema initially. Nevertheless, over time, CTCL can worsen, forming patches, plaques or tumors. As stated earlier, it's part of non-Hodgkin lymphoma. Unlike most lymphomas, though, it doesn't stay in the blood; rather, it shows up and remains in the skin.\nWhile the characteristics of CTCL might sound tolerable relative to aggressive cancers, the sad reality for CTCL patients is that the right treatment solutions can be difficult to find across the disease's progressive spectrum. This is particularly true for...

More updates from Soligenix, Inc.